In recent years, many targeted therapies, such as anaplastic lymphoma kinase (ALK) [5], EGFR [6], ROS1 [7], RET [8], HER2 [9], and MEK [10], have become available for advanced lung cancer, and more are in development [11]. This evidence concerns the gene ALK and lung carcinoma.